Evidence map›Paper›PMID 42840725›Full record

ArticleAtherosclerosis plus2026

Passive E06 IgG reduces lesional PC-OxPL and macrophage accumulation in cholesterol-fed Ldlr

Brian Trausch-Quiróz, Alexandre Normand, Xuchu Que, Elena Alekseeva, Xiaohong Yang, Craig Resch, Amir Ravandi, Joseph L Witztum, Sotirios Tsimikas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Atherosclerosis plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Brian Trausch-QuirózVascular Medicine Program, Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA.
Alexandre NormandVascular Medicine Program, Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA.
Xuchu QueVascular Medicine Program, Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA.
Elena AlekseevaDivision of Endocrinology and Metabolism, University of California San Diego, La Jolla, CA, USA.
Xiaohong YangVascular Medicine Program, Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA.
Craig ReschDepartment of Physiology and Pathophysiology, Rady Faculty of Health Sciences, University of Manitoba, Canada.
Amir RavandiDepartment of Physiology and Pathophysiology, Rady Faculty of Health Sciences, University of Manitoba, Canada.
Joseph L WitztumDivision of Endocrinology and Metabolism, University of California San Diego, La Jolla, CA, USA.
Sotirios TsimikasVascular Medicine Program, Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA.

Funding

Translating Lp(a) biology to clinical applicationsR01HL159156 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SOTIRIOS TSIMIKAS · 2022 to 2026
$3.3M
Aspirin, Lp(a) and Primary Prevention of Cardiovascular EventsR01HL170224 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SOTIRIOS TSIMIKAS · 2023 to 2026
$3.0M
NHLBI NIH HHS R01 HL159156NHLBI NIH HHS R01 HL170224
6 · The paper itself

Abstract

Background: Oxidized phospholipids (OxPL) promote vascular inflammation and atherosclerosis. Although transgenic expression of the E06 single-chain antibody reduces atherosclerosis in mice, the therapeutic potential and mechanism of passive immunization with full-length recombinant E06 IgG remain unknown. Methods: Male Results: Terminal plasma E06 IgG concentrations confirmed dose-dependent systemic exposure. Compared with placebo, E06 IgG significantly reduced lesional macrophage content (47.6 ± 14.5% vs 34.4 ± 9.2% vs 34.3 ± 9.1% of lesion area; Conclusions: These findings provide proof-of-concept that passive E06 IgG selectively neutralizes lesional PC-OxPL and reduces plaque macrophage accumulation despite minimal sustained effects on circulating OxPL, supporting further investigation of OxPL-targeted therapies and suggesting that circulating OxPL may not adequately reflect vascular target engagement.

Indexed as

AtherosclerosisE06 IgGlipoprotein(a)Oxidation-specific epitopesOxidized phospholipidsPassive immunization

Identifiers

PMID42840725
PMCPMC13641036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.